ArticleNPJ precision oncology2026
Valproic acid reverses macrophage-mediated temozolomide resistance in macrophage-rich gliomas.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Glioma therapy often fails due to the acquisition of temozolomide (TMZ) resistance. Antiepileptic drugs, valproic acid (VPA) and levetiracetam (LEV) are commonly used during the perioperative period of glioma patients, and have been proposed for repurposing to augment TMZ efficacy. Our previous studies revealed that LEV could increase TMZ efficacy through downregulation of O-6-methylguanine-DNA methyltransferase (MGMT) and VPA could promote glioma cells apoptosis. Recently, tumor-associated macrophages (TAMs) have been considered as important modulators of TMZ resistance. As for LEV or VPA, which one is better to improve TMZ efficacy for macrophage-rich gliomas remains unclear. In this study, we investigated whether VPA or LEV could mitigate macrophage-mediated exceptional TMZ resistance. Our in vitro experiments revealed that VPA rather than LEV could polarize TAMs into M1 phenotypes. In vivo, glioma mouse models could benefit more from TMZ + VPA regimen by increasing intratumoral M1 macrophage infiltration. We conclude that VPA might be more useful than LEV to improve the therapeutic effect of TMZ for macrophage-rich gliomas. This study provides critical preclinical evidence for the optimal selection of the antiepileptic drug to overcome TAM-mediated chemoresistance, offering translational implications for personalized therapeutic strategies for macrophage-rich gliomas.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.